Out in @Ajhematology: Relapse mechanisms after frontline FLT3 inhibitor therapy in FLT3 #AML include FLT3 loss and emergent non-FLT3 mutations. Post-relapse outcomes are poor, especially in FLT3 mut relapses. @mdanderson.bsky.social #Leukemia doi.org/10.1002/ajh.... #leusm

Please check our recent Seminar review in @thelancet.com discussing the biology of #ALL and evolution of treatment for both pediatric and adult patients @mdanderson.bsky.social #Leukemia www.thelancet.com/journals/lan... #leusm

There have been major advances in #ALL therapy over the last decade. Check out our review just published in Cancer Journal discussing these advances & revolution in adult ALL therapy. @mdanderson.bsky.social #Leukemia doi.org/10.1002/cncr... #leusm

SQ blinatumomab is highly effective in R-R ALL with CR/CRh rate of 77%, MRD-negativity rate of 91%, and 12-month OS rate of 63-70%. The 250 µg/500 µg dose was selected as the recommended phase 2 dose. @mdanderson.bsky.social #Leukemia doi.org/10.1016/s235... #leusm

A comprehensive review on the management of #CML in 2025 written by an international group of CML experts. @mdanderson.bsky.social #Leukemia doi.org/10.1002/cncr... #leusm

WBC >70K (but not IKZF1plus) increases risk of relapse with blina+ponatinib in Ph+ ALL, particularly extramedullary/CNS. Pts with high WBC should be considered for systemic MTX/Ara-C and/or CAR T-cell consolidation @mdanderson.bsky.social jhoonline.biomedcentral.com/articles/10.... #leusm #ALL

New in Leukemia Journal: Outcomes in intensively treated KMT2Ar #AML have improved over time. But low-intensity therapies still show poor results — highlighting the urgent need to explore menin inhibitors www.nature.com/articles/s41... #leusm @mdanderson.bsky.social

Historical development, current status, and future research of olverembatinib, a new third-generation BCR::ABL1 TKI with significant activity and favorable safety profile: @mdanderson.bsky.social #Leukemia dx.doi.org/10.1002/cncr... #leusm #CML

First report of the Ph 2 trial of the CLIA regimen in pts w/ R/R #AML: CR/CRi of 49% & median OS of 12 months in pts who received it as 1st salvage rx. Data provides tolerable & effective backbone upon which to build combination strategies @mdanderson.bsky.social doi.org/10.1002/cncr...

Ph 1b/2 trial of Aza-Ven-Magro in newly-diagnosed high-risk and R/R #AML: Clinical data & correlative analysis @theaacr.bsky.social doi.org/10.1158/1078... Unfortunately, the neg Ph3 ENHANCE trials terminates research w/ Magrolimab and likely anti-CD47 Rx in AML for now @mdanderson.bsky.social

Check out our comprehensive review on #AML from an @mdanderson.bsky.social perspective, " Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges" published in @acsjournalcancer.bsky.social acsjournals.onlinelibrary.wiley.com/doi/10.1002/... #leusm

Check out our comprehensive review of Chronic Myeloid Leukemia published in @jama.com Listen to our interview available through the link: jamanetwork.com/journals/jam... @mdanderson.bsky.social #Leukemia @ EJabbour @drhkantarjian.bsky.social #leusm #CML

In this large retrospective study of FLT3-mutated AML, we confirm the important role of FLT3 inhibitors in intensively treated pts and demonstrate promising outcomes w/ low-intensity triplets in older/unfit pts @mdanderson.bsky.social #Leukemia @americancancersoc.bsky.social doi.org/10.1002/cncr...

Expert recommendations on using MRD in #ALL now out in @bloodadvances.bsky.social. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT @mdanderson.bsky.social #Leukemia doi.org/10.1182/bloo... #leusm

Oral formulation of arsenic trioxide has similar pharmacokinetics to the intravenous drug, allowing potential future all oral therapy in acute promyelocytic leukemia @mdanderson.bsky.social #Leukemia doi.org/10.1182/bloo... @ash.hematology.org #leusm

Updated results of our frontline trial of FLAG-IDA+VEN, showing CRc in 95% of newly diagnosed #AML. Responses were seen across all ELN22 risk groups, w/ 90% MRD neg. In RR AML, 79% first salvage & TP53wt attained CRc. @mdanderson.bsky.social rdcu.be/ebcvm #leusm

Treatment-free remission in non-transplanted Ph+ #ALL pts is feasible in carefully selected pts. Those in CR1 (n=6) who maintained CMR for >48 mos did not relapse following TKI discontinuation. @mdanderson.bsky.social doi.org/10.1002/cncr... @nitinjainmd.bsky.social @niranjankhaire.bsky.social

Early attainment of undetectable MRD by MFC is independently associated w/ improved RFS in newly diagnosed #AML. Intermediate risk pts who attain undetectable MRD should still undergo consolidative allo-SCT. @mdanderson.bsky.social #Leukemia @ash.hematology.org ashpublications.org/bloodadvance...

Genomic secondary #AML: Heterogenous group w/ outcomes variable based on presence of secondary type mutations or cytogenetics @mdanderson.bsky.social #Leukemia Kantarjian, DiNardo, Loghavi, Senapati @jayastumd.bsky.social American Journal of Hematology onlinelibrary.wiley.com/doi/10.1002/... #leusm

Treated secondary #AML is an adverse subtype of AML that warrants an independent prognostic designation @mdanderson.bsky.social #Leukemia Kantarjian, Kadia, Senapati, @jayastumd.bsky.social American Journal of Hematology onlinelibrary.wiley.com/doi/10.1002/... #leusm